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For decades the default treatment for anaemia and bleeding was 
mostly blood transfusion. However, safety risks from new and 
re-emerging pathogens in the blood pool,[1-3] significant inter- and 
intrahospital transfusion variability for matched patients,[4-9] the high 
cost of transfusion therapy,[10,11] and in particular the large number of 
risk-adjusted observational studies demonstrating that transfusion 
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For more than 70 years the default therapy for anaemia and blood loss was mostly transfusion. Accumulating evidence demonstrates a 
significant dose-dependent relationship between transfusion and adverse outcomes. This and other transfusion-related challenges led the 
way to a new paradigm. Patient blood management (PBM) is the application of evidence-based practices to optimise patient outcomes by 
managing and preserving the patient’s own blood. ‘Real-world’ studies have shown that PBM improves patient outcomes and saves money. 
The prevalence of anaemia in adult South Africans is 31% in females and 17% in males. Improving the management of anaemia will firstly 
improve public health, secondly relieve the pressure on the blood supply, and thirdly improve the productivity of the nation’s workforce. 
While high-income countries are increasingly implementing PBM, many middle- and low-income countries are still trying to upscale their 
transfusion services. The implementation of PBM will improve South Africa’s health status while saving costs.
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is independently associated in a dose-dependent relationship with 
adverse outcomes including morbidity and mortality,[12-25] have led 
to questioning of the transfusion paradigm.[26,27] Also, systematic 
reviews and meta-analyses of randomised controlled trials have 
shown either no benefit or increased risks from liberal transfusion 
regimens when compared with more restrictive regimens.[28-32] In 
response to these challenges and with the objectives of better 
addressing the causes or underlying diseases that could potentially 
lead to allogeneic transfusions and offering the best choice of therapy, 
the new paradigm of patient blood management (PBM) has emerged.
PBM is described by the International Foundation for Patient 
Blood Management as ‘an evidence-based bundle of care to optimize 
medical and surgical patient outcomes by clinically managing and 
preserving a patient’s blood’.[33] This is achieved by optimising 
erythropoiesis, minimising blood loss and harnessing or optimising 
the physiological reserves of anaemia while appropriate therapy 
is instituted, often referred to as the ‘three pillars of patient blood 
management’ (Fig. 1). This concept was adopted by the World 
Health Assembly resolution WHA63.12 in 2010.[34] A similar and 
widely used description of PBM by the Society for the Advancement 
of Blood Management is ‘the timely application of evidence-based 
medical and surgical concepts designed to maintain hemoglobin 
concentration, optimize hemostasis and minimize blood loss in an 
effort to improve patient outcome’.[35]
A number of large observational PBM studies have demonstrated 
significantly improved patient outcomes including mortality, 
morbidity and average length of hospital stay,[36-39] one of these 
being a recent ‘real-world study’ with 605 046 patients within the 
jurisdiction of Western Australia (Table 1).[40] Also, a growing number 
of randomised controlled trials looking at single PBM treatment 
modalities showed significantly improved patient outcomes with 
concurrent reduction of blood component utilisation.[41,42] Overall, 
PBM has demonstrated improved outcomes while reducing cost 
and/or resource utilisation (blood components) with the potential to 
repurpose those savings.
PBM as a standard of care
PBM has the potential to address several healthcare-related 
challenges that are specific to South Africa (SA).
First, the population of SA totalled 57.8 million in 2018[43] 
and included an estimated 17.8 million people suffering from 
anaemia, mostly neonates and children, women of reproductive 
age, and the elderly.[44-47] Apart from iron deficiency anaemia, 
there is also a high prevalence of HIV-related anaemia, anaemia 
of inflammation, malarial anaemia and anaemia from intestinal 
parasite infestations. In hospitalised patients, the prevalence of 
anaemia is even higher than in the general population, and 
it is an independent predictor for adverse outcomes including 
morbidity and mortality. [48,49] A secondary analysis of the South 
African Surgical Outcomes Study (SASOS), a large prospective 
observational study of patients undergoing inpatient non-cardiac, 
non-obstetric surgery at 50  hospitals across SA over a 7-day 
period, showed that the prevalence of preoperative anaemia was 
47.8% and that it was independently associated with an increase 
in in-hospital mortality (odds ratio (OR) 1.657, 95% confidence 
interval (CI) 1.055 - 2.602; p=0.028) and admission to critical care 
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• Identify underlying disorder/s causing anaemia
• Manage disorder/s
• Refer for further evaluation if necessary
• Treat suboptimal iron stores/iron deciency/
  anaemia of chronic disease/iron-restricted 
  erythropoiesis
• Treat other haematinic deciencies
• Note: Anaemia is a contraindication to elective 
  surgery
• Time surgery with haematological optimisation
• Optimise erythropoiesis
• Be aware of drug interactions that can increase 
  anaemia
• Identify and manage bleeding risk
• Minimise iatrogenic blood loss
• Procedure planning and rehearsal
• Meticulous haemostasis and surgical techniques
• Blood-sparing surgical devices
• Anaesthetic blood-conserving strategies
• Autologous blood options
• Maintain normothermia
• Pharmacological/haemostatic agents
• Vigilant monitoring and management of 
  postoperative bleeding
• Avoid secondary haemorrhage
• Rapid warming/maintain normothermia 
  (unless hypothermia specically indicated)
• Autologous blood salvage
• Minimise iatrogenic blood loss
• Haemostasis/anticoagulation management
• Prophylaxis of upper GI haemorrhage
• Avoid/treat infections promptly
• Be aware of adverse eects of medication
• Assess/optimise patient's physiological reserve and 
  risk factors
• Compare estimated blood loss with patient-specic 
  tolerable blood loss
• Formulate patient-specic management plan using 
  appropriate blood-conservation modalities to 
  minimise blood loss, optimise red cell mass and 
  manage anaemia
• Optimise cardiac output
• Optimise ventilation and oxygenation
• Optimise anaemia reserve
• Maximise oxygen delivery
• Minimise oxygen consumption
• Avoid/treat infections promptly
• Restrictive transfusion thresholds
Perioperative multidisciplinary multimodal patient-specic team approach
Second pillar
Minimise blood loss and bleeding
Third pillar
Harness and optimise 
physiological reserve of anaemia
Fig. 1. The three-pillar, nine-field matrix of PBM. This matrix was designed for the Western Australia Patient Blood Management Program to assist in 
the clinical implementation of the multiple PBM strategies. These strategies are considered in the perioperative period in a patient- and procedure-specific 
context. [89] The principles of this matrix were also applied to non-surgical patients before, during and after treatment. (PBM = patient blood management.)
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(OR 1.487, 95% CI  1.081 - 2.046; p=0.015).[50] For these reasons, 
the implementation of PBM including anaemia management and 
bleeding management represents a major opportunity to sustainably 
improve public health in SA in respect of:
• child mortality
• maternal mortality (particularly related to peri- and postpartum 
haemorrhage)
• anaemia-related adverse outcomes
• blood loss and bleeding-related adverse outcomes
• transfusion-related adverse outcomes
• overall surgical and medical outcomes in hospitalised patients.
Second, the implementation of PBM would ease the pressure on 
the nation’s blood supply. The high prevalence of anaemia, the 
high prevalence of HIV with the world’s highest absolute number 
of cases,[51] and other frequently occurring diseases have led to a 
particularly high rate of 20% blood donor deferrals (Dr Jaqueline 
Thomson, Medical Director, South African National Blood Service, 
personal communication, 2018). At the same time, the demand for 
blood components is expected to increase owing to HIV-related 
anaemia and the population segment aged ≥65 years that is now 
growing faster than previously.[52] As a consequence, the prevalence 
of chronic disease and surgical procedures is expected to rise, with a 
concomitant increased demand for blood unless there are immediate 
and widespread practice changes.
Third, there is also an overall economic argument for the 
implementation of PBM. Unmanaged or poorly managed anaemia 
impairs the cognitive development of children and adolescents, 
reduces the ability to concentrate, and diminishes work productivity 
with losses in some countries of up to 9% of the gross domestic 
product.[53] Programmes promoting oral iron therapy may be 
effective in specific subpopulations, but in patients with profound 
iron deficiency and iron deficiency anaemia, who require therapy 
for immediate correction, an appropriate dose of intravenous iron 
is the best option, while treatment of the underlying cause produces 
a cure. [54] Improvements in patient outcomes with the concomitant 
savings as seen in previous studies could lead to a significant decrease 
in bed occupation and relieve a healthcare budget under extreme 
pressure.[42,55]
Contradictory developments:  
PBM for high-income countries  
and transfusion for the rest?
In the healthcare systems of the advanced economies, both the 
private and public sectors have begun to move their focus towards 
pre-empting the causes for transfusion through PBM rather than 
expanding the infrastructure to advance transfusion therapy.[56] 
The full implementation of PBM as a bundle of care is challenging, 
and some institutions are therefore following the recommendation 
of a stepwise implementation by introducing a series of simple 
PBM measures.[57,58] Others are choosing comprehensive change 
management methodologies and multi-stakeholder management 
to achieve relatively fast and system-wide implementation.[40] The 
variable implementation methodologies, and also differences in 
hospital cultures, may explain why the implementation of PBM 
remains extremely variable across many of the high-income 
countries. [59] However, the underlying rationale for this patient-centric 
approach is simple and compelling: PBM is not only associated with 
a better outcome, but also with less cost.[36,38,40] Consequently, PBM 
keeps growing while blood services are experiencing a significant 
decline in blood utilisation and therefore re-engineer, downsize 
operations, or merge with other regional blood services.[56,60]
In contrast, in many emerging and frontier economies, the focus 
of health authorities is still on modernising blood services to match 
quality levels comparable to those in the advanced economies and on 
establishing additional blood centres.[61-70] This expansion results in 
significant new investments and adds to the already large expenses 
of maintaining these services. In view of the poor cost-effectiveness 
of blood safety interventions and of transfusion therapy,[71-73] it 
is inappropriate use of limited financial resources. The decision 
to allocate more resources to supporting the product-focused 
transfusion model rather than the patient-centric PBM model could 
be likened to the establishment of landlines in a geographical area 
bare of communication infrastructure rather than setting up highly 
effective and much less costly mobile phone networks de novo.
In view of the burgeoning clinical data on adverse transfusion 
outcomes, the ongoing blood safety issues, the pervasive blood 
sourcing problems and the overall health-economic constraints, 
it would be both unethical and paradoxical to continue to invest 
Table 1. Summary of study results from the Western Australia Patient Blood Management Program, 2008 - 2012 (N=605 046), 
comparing baseline year (2008/09) with year 6 (2013/14) (adapted from Leahy et al.[40])
Patient outcomes Adjusted ratios (95% CI) p-value
In-hospital mortality 0.72 (0.67 - 0.77) <0.001
Hospital-acquired infections 0.79 (0.73 - 0.86) <0.001
Acute myocardial infarction/stroke 0.69 (0.58 - 0.82) <0.001
Length of hospital stay 0.85 (0.84 - 0.87) <0.001
All-cause emergency readmission 1.06 (1.02 - 1.10) <0.001
Key programme indicators Change
Preoperative anaemia 21% to 14% 0.001
Pre-transfusion haemoglobin 7.9 g/dL to 7.3 g/dL <0.001
Single-unit transfusions 33% to 64% <0.001
Type of blood product Reduction of units transfused




Blood product cost reduction AUD18.5 million
Activity-based cost reduction (estimate) AUD80 - 100 million
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financial and human resources into the fading model of traditional 
blood banking while neglecting the implementation of PBM.[74]
Seizing the opportunity to improve 
SA’s health status and patient safety 
while saving costs
With combined support from both the public and private sectors, 
including the professional medical societies, academia, healthcare 
providers, funders, blood services and patient organisations and 
the endorsement of SA’s National Department of Health, a guiding 
coalition of PBM champions should take the opportunity to establish 
PBM as a new standard of care that offers a win-win scenario.[75]
PBM has become a national priority of the Australian Commission 
on Safety and Quality in Health Care,[76] and stakeholders in the 
public and private healthcare sectors of other countries have 
the opportunity to learn from the results of the state-wide PBM 
quality, safety and effectiveness initiative in Western Australia that 
significantly improved outcomes and achieved a sizeable cost and 
resource utilisation reduction.[40] They may benefit from the freely 
available multidisciplinary clinical PBM guidelines and algorithms.
[77-83] With local adaptations they may also use the European 
Commission’s guides for hospitals and health authorities on how 
to implement PBM sustainably as a national standard of care.[84,85] 
Additional lessons can be learned from blood services in foreign 
countries that are now embracing implementation of PBM as one of 
their core activities.[86-88]
Compelling evidence, newly gained international experience and 
many freely available tools and templates are now allowing progress 
to be quickly achieved with a series of single, evidence-based PBM 
interventions, or preferably PBM pilot programmes to be started in 
both the public and private sectors, gradually adjusting and refining 
contents to local needs and finally implementing PBM as a national 
standard of care.
Discussion
This article first describes why in many clinical settings the 
transfusion paradigm is fading while the PBM paradigm is rising. 
Overall, the evidence demonstrates that correcting anaemia 
through stimulated erythropoiesis, minimising blood loss through 
anaesthetic and surgical techniques, and optimising coagulation 
status before and during surgical or other interventions are 
associated with significantly better outcomes and less cost than the 
decades-old practice of transfusing allogeneic blood components. 
Then, the authors explain why implementation of PBM represents 
a solution to many of SA’s health, healthcare and economic 
challenges. PBM would effectively reduce the prevalence of anaemia, 
which owing to the country’s specific circumstances is higher 
than in many other countries. In combination with optimised 
bleeding and coagulation management, this reduction would have 
a positive effect on child and maternal mortality. Overall, based 
on international study results and in the context of secondary 
analysis of the SASOS, a large number of hospitalised medical and 
surgical patients would benefit from PBM. Its implementation 
would also decrease the demand for allogeneic blood components, 
thus easing the chronic pressure on the nation’s blood supply, 
which has a high number of donor restrictions as a result of 
HIV-related and other transmissible diseases. PBM would also 
contribute to socioeconomic improvements. Fewer complications, 
reduced morbidity and reduced hospital length of stay could lead 
to significant cost savings that could be reallocated to other areas 
of unmet clinical need. Optimal anaemia management, central to 
PBM, would also improve the cognitive development of children 
and adolescents, thus positively influencing productivity and the 
gross domestic product and the quality of life in SA.
The authors also allude to an important cultural aspect when 
it comes to the implementation of PBM: health authorities have 
traditionally focused on the supply of, not the demand for, blood. 
For decades, the legislation and administration of the ‘blood sector’ 
revolved around the concept that red blood cell transfusion is 
the only way of treating anaemia and blood loss. Therefore, the 
permanent and ubiquitous availability of safe donor blood was 
considered indispensable to keep clinical services operational, while 
the financial aspects of blood safety measures played only a minor 
role. However, with the introduction of evidence-based patient and 
disease management through PBM, other treatment options are now 
preferred, and in many clinical scenarios, blood transfusions are less 
frequently used or have even become obsolete.
Although this reversal of trends can now be observed in many 
modern healthcare systems, it may be challenging for health 
authorities to change focus, particularly when current efforts are still 
geared towards expansion of blood services. PBM will clearly impact 
a lot more on reducing the number of transfused blood components 
than any effort of the blood centres to increase the number of blood 
collections.
This article should be understood as a call to action to significantly 
improve the quality, safety and effectiveness of healthcare in SA. 
First, health authorities, medical professionals, funders and all other 
relevant stakeholders need to be thoroughly informed about the 
evidence on the multiple wins with PBM. This knowledge should 
lead to their acknowledgement and official endorsement of PBM 
and active support to implement it. Second, multidisciplinary peer-
reviewed guidelines, algorithms and other useful tools for PBM, that 
have already been developed in other parts of the world and are freely 
accessible, need to be adapted to the local needs of SA. This should 
primarily take place with the active involvement of all the relevant 
professional medical societies in SA. Third, PBM pilot projects in 
the public and private sectors should be carried out to test and refine 
PBM in the current healthcare framework, and finally, PBM should 
be implemented as a mandatory national standard of care.
Conclusions
The rapid implementation of PBM as a new standard of care is an 
urgent need. It offers the opportunity to sustainably and significantly 
improve the health status of the people of SA, with the potential of 
enormous savings for the healthcare system. 
Declaration. None.
Acknowledgements. We gratefully acknowledge David M Mngomezulu, 
MD, for his insightful comments and his clear call for action regarding the 
implementation of PBM in SA.
Author contributions. JT and AH contributed equally to this article. JT, AH, 
RW and AS conceptualised and wrote the manuscript. CAB, AB, GRMB, 
LB, MWG, HHG, CH, CK, VJL, CL, CBN, VR, FS, EV, P-LW and PW 
reviewed and edited the manuscript. SF reviewed and edited the manuscript 
and jointly with AH provided the figure and table data. JNM and MJC 
reviewed and edited the manuscript and helped prepare it for submission.
Funding. None.
Conflicts of interest.  JT has received honoraria from Takeda. AH has 
received honoraria and travel support from Vifor, Fresenius, Medical Care 
Renal and Werfen and travel support from the South African National 
Blood Service. VJL has received honoraria and travel support from Litha 
Healthcare, Pharmacosmos, Takeda and Vifor Pharma, and is also a 
475       July 2019, Vol. 109, No. 7
IN PRACTICE
non-executive director of the Western Cape Blood Service. AS reports 
grants from CSL Behring, HbO2 Therapeutics, LLC, Instrumentation 
Laboratory and Masimo Corporation, has received honoraria from CSL 
Behring, Masimo Corporation, Merck and Portola Pharmaceuticals, and 
has been a consultant for AMAG, CSL Behring, HbO2 Therapeutics, 
LLC, Instrumentation Laboratory, Masimo Corporation, Portola 
Pharmaceuticals and Vifor Pharma. There are no conflicts of interest for 
the other authors.
1. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin 
Hematol 2007;44(1):32-41. https://doi.org/10.1053/j.seminhematol.2006.09.016
2. Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential 
threat to transfusion safety. Transfusion 2009;49(Suppl 2):1S-29S. https://doi.org/10.1111/j.1537-
2995.2009.02279.x
3. Snyder EL, Stramer SL, Benjamin RJ. The safety of the blood supply – time to raise the bar. N Engl J 
Med 2015;372(20):1882-1885. https://doi.org/10.1056/NEJMp1500154
4. Stover EP, Siegel LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass 
surgery persists despite national consensus guidelines: A 24-institution study. Institutions of the 
Multicenter Study of Perioperative Ischemia Research Group. Anesthesiology 1998;88(2):327-333.
5. Bennett-Guerrero E, Zhao Y, O’Brien SM, et al. Variation in use of blood transfusion in coronary artery 
bypass graft surgery. JAMA 2010;304(14):1568-1575. https://doi.org/10.1001/jama.2010.1406
6. Snyder-Ramos SA, Mohnle P, Weng YS, et al. The ongoing variability in blood transfusion practices in 
cardiac surgery. Transfusion 2008;48(7):1284-1299. https://doi.org/10.1111/j.1537-2995.2008.01666.x
7. Gombotz H, Rehak PH, Shander A, Hofmann A. Blood use in elective surgery: The Austrian benchmark 
study. Transfusion 2007;47(8):1468-1480. https://doi.org/10.1111/j.1537-2995.2007.01286.x
8. Baele PL, de Bruyere M, Deneys V, et al. The SANGUIS Study in Belgium: An overview of methods and 
results. Safe and good use of blood in surgery. Acta Chir Belg 1994;94(2):69-74.
9. Zhu C, Gao Y, Li Z, et al. A systematic review and meta-analysis of the clinical appropriateness of blood 
transfusion in China. Medicine 2015;94(50):e2164. https://doi.org/10.1097/MD.0000000000002164
10. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of 
blood transfusions in surgical patients at four hospitals. Transfusion 2010;50(4):753-765. https://doi.
org/10.1111/j.1537-2995.2009.02518.x
11. Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma transfusions in medical and surgical 
inpatients at a US hospital. Vox Sang 2016;111(1):55-61. https://doi.org/10.1111/vox.12386
12. Whitlock EL, Kim H, Auerbach AD. Harms associated with single unit perioperative transfusion: 
Retrospective population based analysis. BMJ 2015;350:h3037. https://doi.org/10.1136/bmj.h3037
13. Patel SV, Kidane B, Klingel M, Parry N. Risks associated with red blood cell transfusion in the 
trauma population, a meta-analysis. Injury 2014;45(10):1522-1533. https://doi.org/10.1016/j.
injury.2014.05.015
14. Ferraris VA, Davenport DL, Saha SP, Austin PC, Zwischenberger JB. Surgical outcomes and 
transfusion of minimal amounts of blood in the operating room. Arch Surg 2012;147(1):49-55. https://
doi.org/10.1001/archsurg.2011.790
15. Mikkola R, Gunn J, Heikkinen J, et al. Use of blood products and risk of stroke after coronary artery 
bypass surgery. Blood Transfus 2012;10(4):490-501. https://doi.org/10.2450/2012.0119-11
16. Al-Refaie WB, Parsons HM, Markin A, Abrams J, Habermann EB. Blood transfusion and cancer 
surgery outcomes: A continued reason for concern. Surgery 2012;152(3):344-354. https://doi.
org/10.1016/j.surg.2012.06.008
17. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood transfusions, 
thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168(21):2377-
2381. https://doi.org/10.1001/archinte.168.21.2377
18. Horvath KA, Acker MA, Chang H, et al. Blood transfusion and infection after cardiac surgery. Ann 
Thorac Surg 2013;95(6):2194-2201. https://doi.org/10.1016/j.athoracsur.2012.11.078
19. Bernard AC, Davenport DL, Chang PK, Vaughan TB, Zwischenberger JB. Intraoperative transfusion of 
1 U to 2 U packed red blood cells is associated with increased 30-day mortality, surgical-site infection, 
pneumonia, and sepsis in general surgery patients. J Am Coll Surg 2009;208(5):931-937, 937.e1-2; 
discussion 938-939. https://doi.org/10.1016/j.jamcollsurg.2008.11.019
20. Goel R, Patel EU, Cushing MM, et al. Association of perioperative red blood cell transfusions with 
venous thromboembolism in a North American registry. JAMA Surg 2018;153(9):826-833. https://doi.
org/10.1001/jamasurg.2018.1565
21. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: A systematic review of 
the literature. Crit Care Med 2008;36(9):2667-2674. https://doi.org/10.1097/CCM.0b013e3181844677
22. Murphy GJ, Reeves BC, Rogers CA, Rizvi SI, Culliford L, Angelini GD. Increased mortality, 
postoperative morbidity, and cost after red blood cell transfusion in patients having cardiac surgery. 
Circulation 2007;116(22):2544-2552. https://doi.org/10.1161/CIRCULATIONAHA.107.698977
23. Xenos ES, Vargas HD, Davenport DL. Association of blood transfusion and venous thromboembolism 
after colorectal cancer resection. Thromb Res 2012;129(5):568-572. https://doi.org/10.1016/j.
thromres.2011.07.047
24. Van Straten AH, Bekker MW, Soliman Hamad MA, et al. Transfusion of red blood cells: The impact on 
short-term and long-term survival after coronary artery bypass grafting, a ten-year follow-up. Interact 
Cardiovasc Thorac Surg 2010;10(1):37-42. https://doi.org/10.1510/icvts.2009.214551
25. Paone G, Likosky DS, Brewer R, et al. Transfusion of 1 and 2 units of red blood cells is associated with 
increased morbidity and mortality. Ann Thorac Surg 2014;97(1):87-93; discussion 93-84. https://doi.
org/10.1016/j.athoracsur.2013.07.020
26. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused 
transfusion practice to patient blood management. Oncologist 2011;16(Suppl 3):3-11. https://doi.
org/10.1634/theoncologist.2011-S3-3
27. Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion 
outcomes: Establishing causation. Transfus Med Rev 2011;25(2):89-101. https://doi.org/10.1016/j.
tmrv.2010.11.001
28. Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic 
red blood cell transfusion. Cochrane Database Syst Rev 2012, Issue 4. Art. No.: CD00204. https://doi.
org/10.1002/14651858.CD002042.pub3
29. Rohde JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell 
transfusion: A systematic review and meta-analysis. JAMA 2014;311(13):1317-1326. https://doi.
org/10.1001/jama.2014.2726
30. Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J. Restrictive versus liberal transfusion strategy 
for red blood cell transfusion: Systematic review of randomised trials with meta-analysis and trial 
sequential analysis. BMJ 2015;350:h1354. https://doi.org/10.1136/bmj.h1354
31. Salpeter SR, Buckley JS, Chatterjee S. Impact of more restrictive blood transfusion strategies on clinical 
outcomes: A meta-analysis and systematic review. Am J Med 2014;127(2):124-131.e3. https://doi.
org/10.1016/j.amjmed.2013.09.017
32. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding 
allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2016, Issue 10. Art. No.: CD002042. 
https://doi.org/10.1002/14651858.CD002042.pub4
33. International Foundation for Patient Blood Management. What is patient blood management? https://
www.ifpbm.org (accessed 15 September 2018).
34. World Health Organization. Sixty-Third World Health Assembly, Resolution WHA63.12, Agenda item 
11.17 on availability, safety and quality of blood products. 21 May 2010. http://apps.who.int/gb/ebwha/
pdf_files/WHA63/A63_R12-en.pdf (accessed 24 October 2018).
35. Society for the Advancement of Blood Management. Definition of patient blood management. https://
www.sabm.org (accessed 15 September 2018).
36. Mehra T, Seifert B, Bravo-Reiter S, et al. Implementation of a patient blood management monitoring 
and feedback program significantly reduces transfusions and costs. Transfusion 2015;55(12):2807-
2815. https://doi.org/10.1111/trf.13260
37. Freedman J. The ONTraC Ontario program in blood conservation. Transfus Apher Sci 2014;50(1):32-
36. https://doi.org/10.1016/j.transci.2013.12.010
38. Frank SM, Thakkar RN, Podlasek SJ, et al. Implementing a health system-wide patient blood 
management program with a clinical community approach. Anesthesiology 2017;127(5):754-764. 
https://doi.org/10.1097/ALN.0000000000001851
39. Gupta PB, DeMario VM, Amin RM, et al. Patient blood management program improves blood use 
and clinical outcomes in orthopedic surgery. Anesthesiology 2018;129(6):1082-1091. https://doi.
org/10.1097/ALN.0000000000002397
40. Leahy MF, Hofmann A, Towler S, et al. Improved outcomes and reduced costs associated with a health-
system-wide patient blood management program: A retrospective observational study in four major 
adult tertiary-care hospitals. Transfusion 2017;57(6):1347-1358. https://doi.org/10.1111/trf.14006
41. Khalafallah AA, Yan C, Al-Badri R, et al. Intravenous ferric carboxymaltose versus standard care in the 
management of postoperative anaemia: A prospective, open-label, randomised controlled trial. Lancet 
Haematol 2016;3(9):e415-e425. https://doi.org/10.1016/S2352-3026(16)30078-3
42. Froessler B, Palm P, Weber I, Hodyl NA, Singh R, Murphy EM. The important role for intravenous iron 
in perioperative patient blood management in major abdominal surgery: A randomized controlled 
trial. Ann Surg 2016;264(1):41-46. https://doi.org/10.1097/SLA.0000000000001646
43. Statistics South Africa. Mid-year population estimates 2018. Statistical release P0302. Pretoria: Stats 
SA, 2018. https://www.statssa.gov.za/publications/P0302/P03022018.pdf (accessed 28 May 2019).
44. Kassebaum NJ; GBD 2013 Anemia Collaborators. The global burden of anemia. Hematol Oncol Clin 
North Am 2016;30(2):247-308. https://doi.org/10.1016/j.hoc.2015.11.002
45. Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis of global anemia burden from 1990 
to 2010. Blood 2014;123(5):615-624. https://doi.org/10.1182/blood-2013-06-508325
46. Vos T, Allen C, Arora M, et al. Global, regional, and national incidence, prevalence, and years 
lived with disability for 310 diseases and injuries, 1990 - 2015: A systematic analysis for the Global 
Burden of Disease Study 2015. Lancet 2016;388(10053):1545-1602. https://doi.org/10.1016/S0140-
6736(16)31678-6
47. Payne CF, Davies JI, Gomez-Olive FX, et al. Cross-sectional relationship between haemoglobin 
concentration and measures of physical and cognitive function in an older rural South African 
population. J Epidemiol Community Health 2018;72(9):796-802. https://doi.org/10.1136/jech-2018-
210449
48. Fowler AJ, Ahmad T, Phull MK, Allard S, Gillies MA, Pearse RM. Meta-analysis of the association 
between preoperative anaemia and mortality after surgery. Br J Surg 2015;102(11):1314-1324. https://
doi.org/10.1002/bjs.9861
49. Munoz M, Gomez-Ramirez S, Kozek-Langeneker S, et al. ‘Fit to fly’: Overcoming barriers to 
preoperative haemoglobin optimization in surgical patients. Br J Anaesth 2015;115(1):15-24. https://
doi.org/10.1093/bja/aev165
50. Marsicano D, Hauser N, Roodt F, et al. Preoperative anaemia and clinical outcomes in the South 
African Surgical Outcomes Study. S Afr Med J 2018;108(10):839-846. https://doi.org/10.7196/
SAMJ.2018.v108i10.13148
51. Joint United Nations Programme on HIV and AIDS. Country overview South Africa. http://www.
unaids.org/en/regionscountries/countries/southafrica (accessed 15 September 2018 2018).
52. United Nations DESA/Population Division. World population prospects: The 2017 revision. 2017. 
https://esa.un.org/unpd/wpp/ (accessed 15 October 2018).
53. Horton S, Ross J. The economics of iron deficiency. Food Policy 2003;28(1):51-75. https://doi.
org/10.1016/S0306-9192(02)00070-2
54. Munoz M, Gomez-Ramirez S, Besser M, et al. Current misconceptions in diagnosis and management 
of iron deficiency. Blood Transfus 2017;15(5):422-437. https://doi.org/10.2450/2017.0113-17
55. Froessler B, Rueger AM, Connolly MP. Assessing the costs and benefits of perioperative iron deficiency 
anemia management with ferric carboxymaltose in Germany. Risk Manag Healthc Policy 2018;11:77-
82. https://doi.org/10.2147/RMHP.S157379
56. Klein HG, Hrouda JC, Epstein JS. Crisis in the sustainability of the U.S. blood system. N Engl J Med 
2017;377(15):1485-1488. https://doi.org/10.1056/NEJMsb1706496
57. Meybohm P, Froessler B, Goodnough LT, et al. ‘Simplified International Recommendations for the 
Implementation of Patient Blood Management’ (SIR4PBM). Perioper Med 2017;6:5. https://doi.
org/10.1186/s13741-017-0061-8
58. Althoff FC, Neb H, Herrmann E, et al. Multimodal patient blood management program based on a 
three-pillar strategy: A systematic review and meta-analysis. Ann Surg 2019;269(5):794-804. https://
doi.org/10.1097/SLA.0000000000003095
59. Van der Linden P, Hardy JF. Implementation of patient blood management remains extremely variable 
in Europe and Canada: The NATA benchmark project. Eur J Anaesthesiol 2016;33(12):913-921. 
https://doi.org/10.1097/EJA.0000000000000519
60. Carson JL, Triulzi DJ, Ness PM. Indications for and adverse effects of red-cell transfusion. N Engl J 
Med 2017;377(13):1261-1272. https://doi.org/10.1056/NEJMra1612789
61. Katz LM, Donnelly JJ, Gresens CJ, et al. Report of a workshop on ensuring sustainable access to 
safe blood in developing countries: International Blood Safety Forum, March 24, 2017. Transfusion 
2018;58(5):1299-1306. https://doi.org/10.1111/trf.14591
62. Sood R, Raykar N, Till B, Shah H, Roy N. Walking blood banks: An immediate solution to rural India’s 
blood drought. Indian J Med Ethics 2018;3(2):134-137. https://doi.org/10.20529/IJME.2017.098
63. Spiegel DA, Droti B, Relan P, Hobson S, Cherian MN, O’Neill K. Retrospective review of surgical 
availability and readiness in 8 African countries. BMJ Open 2017;7(3):e014496. https://doi.
org/10.1136/bmjopen-2016-014496
64. Jain Y, Kataria R. Rural blood availability: Regulations must meet ethics. Indian J Med Ethics 
2016;1(4):237-242. https://doi.org/10.20529/IJME.2016.068
65. Hussein J, Hirose A, Owolabi O, Imamura M, Kanguru L, Okonofua F. Maternal death and obstetric 
care audits in Nigeria: A systematic review of barriers and enabling factors in the provision of 
emergency care. Reprod Health 2016;13:47. https://doi.org/10.1186/s12978-016-0158-4
66. Pitman JP, Wilkinson R, Basavaraju SV, et al. Investments in blood safety improve the availability of 
blood to underserved areas in a sub-Saharan African country. ISBT Sci Ser 2014;9(2):325-333. https://
doi.org/10.1111/voxs.12107
67. Compaore GD, Sombie I, Ganaba R, et al. Readiness of district and regional hospitals in Burkina Faso 
to provide caesarean section and blood transfusion services: A cross-sectional study. BMC Pregnancy 
Childbirth 2014;14:158. https://doi.org/10.1186/1471-2393-14-158
476       July 2019, Vol. 109, No. 7
IN PRACTICE
68. Lund TC, Hume H, Allain JP, McCullough J, Dzik W. The blood supply in sub-Saharan Africa: 
Needs, challenges, and solutions. Transfus Apher Sci 2013;49(3):416-421. https://doi.org/10.1016/j.
transci.2013.06.014
69. Dzik WS, Kyeyune D, Otekat G, et al. Transfusion medicine in Sub-Saharan Africa: Conference 
summary. Transfus Med Rev 2015;29(3):195-204. https://doi.org/10.1016/j.tmrv.2015.02.003
70. Chevalier MS, Kuehnert M, Basavaraju SV, Bjork A, Pitman JP. Progress toward strengthening 
national blood transfusion services – 14 countries, 2011 - 2014. MMWR Morb Mortal Wkly Rep 
2016;65(5):115-119. https://doi.org/10.15585/mmwr.mm6505a4
71. Vamvakas EC. Establishing causation in transfusion medicine and related tribulations. Transfus Med 
Rev 2011;25(2):81-88. https://doi.org/10.1016/j.tmrv.2010.11.010
72. Custer B, Hoch JS. Cost-effectiveness analysis: What it really means for transfusion medicine decision 
making. Transfus Med Rev 2009;23(1):1-12. https://doi.org/10.1016/j.tmrv.2008.09.001
73. Hofmann A, Ozawa S, Farrugia A, Farmer SL, Shander A. Economic considerations on transfusion 
medicine and patient blood management. Best Pract Res Clin Anaesthesiol 2013;27(1):59-68. https://
doi.org/10.1016/j.bpa.2013.02.001
74. Anthes E. Evidence-based medicine: Save blood, save lives. Nature 2015;520(7545):24-26. https://doi.
org/10.1038/520024a
75. Spahn DR, Theusinger OM, Hofmann A. Patient blood management is a win-win: A wake-up call. Br J 
Anaesth 2012;108(6):889-892. https://doi.org/10.1093/bja/aes166
76. Australian Commission on Safety and Quality in Health Care. The National Patient Blood Management 
Collaborative. https://www.safetyandquality.gov.au/national-priorities/pbm-collaborative/ (accessed 
3 February 2018).
77. National Blood Authority, Australia. Patient Blood Management Guidelines: Module 1. Critical 
bleeding/massive transfusion. 1 March 2011. http://www.blood.gov.au/pbm-module-1 (accessed 
15 September 2018).
78. National Blood Authority, Australia. Patient Blood Management Guidelines: Module 2. Perioperative. 
9 March 2012. http://www.blood.gov.au/pbm-module-2 (accessed 15 September 2018).
79. National Blood Authority, Australia. Patient Blood Management Guidelines: Module 3. Medical. 
19 September 2012. http://www.blood.gov.au/pbm-module-3 (accessed 15 September 2018).
80. National Blood Authority, Australia. Patient Blood Management Guidelines: Module 4. Critical care. 
April 2013. http://www.blood.gov.au/pbm-module-4 (accessed 15 September 2018).
81. National Blood Authority, Australia. Patient Blood Management Guidelines: Module 5. Obstetrics and 
maternity. 23 March 2015. https://www.blood.gov.au/pbm-module-5 (accessed 15 September 2018).
82. National Blood Authority, Australia. Patient Blood Management Guidelines: Module 6. Neonatal and 
paediatrics. 29 April 2016. https://www.blood.gov.au/pbm-module-6 (accessed 15 September 2018).
83. Society for the Advancement of Blood Management. SABM Administrative and Clinical Standards 
for Patient Blood Management Programs. 4th ed. 2017. https://www.sabm.org/publications/ (accessed 
15 September 2018).
84. Gombotz H, Hofmann A, Nørgaard A, Kastner P. Supporting Patient Blood Management (PBM) in the 
EU: A Practical Implementation Guide for Hospitals. Brussels: European Commission, Directorate-
General for Health and Food Safety, 2017. https://publications.europa.eu/en/publication-detail/-/
publication/93e1bbbf-1a8b-11e7-808e-01aa75ed71a1/language-en (accessed 28 May 2019).
85. Hofmann A, Nørgaard A, Kurz J, et al. Building National Programmes on Patient Blood Management 
(PBM) in the EU: A Guide for Health Authorities. Brussels: European Commission, Directorate-
General for Health and Food Safety, 2017.
86. Vaglio S, Gentili S, Marano G, et al. The Italian regulatory guidelines for the implementation of patient 
blood management. Blood Transfus 2017;15:325-328. https://doi.org/10.2450/2017.0060-17
87. Vaglio S, Prisco D, Biancofiore G, et al. Recommendations for the implementation of a patient blood 
management programme: Application to elective major orthopaedic surgery in adults. Blood Transfus 
2015;14:23-65. https://doi.org/10.2450/2015.0172-15
88. American Association of Blood Banks Standards Program Committee. Standards for a Patient Blood 
Management Program. 2nd ed. AABB, 2018.
89. Hofmann A, Friedman D, Farmer S. Western Australia Patient Blood Management Project 2008 - 2012: 
Analysis, Strategy, Implementation and Financial Projections. Perth, Western Australia: Medicine and 
Economics, 2007.
Accepted 7 May 2019.
